Fu, J., Li, S., Ma, H., Yang, J., Brown, L. M., Pagnotti, G. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2022). The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease. Blood, 140(Supplement 1), 9930–9932. https://doi.org/10.1182/blood-2022-169921

Scalia, S., Toskic, D., Zhou, P., Mansukhani, M. M., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients. Blood, 140(Supplement 1), 10120–10121. https://doi.org/10.1182/blood-2022-162352

Usmani, S., Patel, K., Hari, P., Berdeja, J., Alsina, M., Vij, R., Raje, N., Leleu, X., Dhodapkar, M., Reshef, R., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Ananthakrishnan, R., Greggio, C., Favre-Kontula, L., Sternas, L., & San-Miguel, J. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140(Supplement 1), 875–877. https://doi.org/10.1182/blood-2022-162469

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Marańda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Shah, N. N., Coombs, C. C., Ujjani, C. S., Patel, M. R., Fakhri, B., Cheah, C. Y., Alencar, A. J., Cohen, J. B., … Jurczak, W. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 2316–2320. https://doi.org/10.1182/blood-2022-159497

Lim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S., Sachsenmeier, K. F., Russell, D. L., Moorthy, G., Sidders, B. S., Pilling, E. A., Chen, H., Hattersley, M. M., Das, M., Kumar, R., Pouliot, G. P., & Patel, M. R. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research, 28(22), 4871–4884. https://doi.org/10.1158/1078-0432.ccr-22-0612

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Chakraborty, R., Behera, T. R., Li, H., Dean, R. M., Hill, B. T., Jagadeesh, D., Winter, A., Anwer, F., Pohlman, B., Sobecks, R. M., Hamilton, B. K., & Majhail, N. S. (2022). Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study. Blood, 140(Supplement 1), 10926–10927. https://doi.org/10.1182/blood-2022-166904

Frangoul, H., Locatelli, F., Bhatia, M., Mapara, M. Y., Molinari, L., Sharma, A., Lobitz, S., de Montalembert, M., Rondelli, D., Steinberg, M., Walters, M. C., Imren, S., Zhang, L., Sharma, A., Song, Y., Simard, C., Hobbs, W., & Grupp, S. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood, 140(Supplement 1), 29–31. https://doi.org/10.1182/blood-2022-162353

Naqvi, S. A. A., Fatima, S., Asghar, N., Ijaz, H., Ayaz, A., He, H., Husnain, M., Chakraborty, R., Riaz, I., & Aljama, M. A. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood, 140(Supplement 1), 10111–10113. https://doi.org/10.1182/blood-2022-170869

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2022). MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism. Blood, 140(Supplement 1), 4224–4225. https://doi.org/10.1182/blood-2022-168314

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432

Mohyuddin, G. R., Chakraborty, R., Calip, G., Ascha, M. S., Wang, X., Rubinstein, S., Tuchman, S. A., Costa, L. J., Haaland, B., Giri, S., Mian, H. S., Fonseca, R., & Sborov, D. W. (2022). Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood, 140(Supplement 1), 5223–5224. https://doi.org/10.1182/blood-2022-165541

Orlando, E., Ford, M., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation. Blood, 140(Supplement 1), 12085–12086. https://doi.org/10.1182/blood-2022-158050

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969

Chakraborty, R., Sexton, R., Lentzsch, S., Abidi, M. H., Voorhees, P. M., Cohen, A. D., Rohren, E., Heitner, S. B., Kelly, K. R., Mackler, N. J., Baer, D. M., Hoering, A., Durie, B. G. M., Ailawadhi, S., & Orlowski, R. Z. (2022). Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib. Blood, 140(Supplement 1), 4349–4351. https://doi.org/10.1182/blood-2022-166609

Estrella, B., Pazos, M. A., Ricker, E. C., Ryu, Y. K., Piorczynski, T. B., Liu, Y., Tolu, S., & Amengual, J. E. (2022). First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade. Blood, 140(Supplement 1), 358–359. https://doi.org/10.1182/blood-2022-166929

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Mosialou, I., Ali, A. M., Adams, R., Corper, A., Woods, C. M., Fan, X., Raza, A., & Kousteni, S. (2022). Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance. Blood, 140(Supplement 1), 2902–2902. https://doi.org/10.1182/blood-2022-167042

Walters, M. C., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M. Y., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Miller, A., Zhang, L., Chawla, A., Macari, E. R., Pierciey, F. J., Tisdale, J. F., & Kanter, J. (2022). Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. Blood, 140(Supplement 1), 26–28. https://doi.org/10.1182/blood-2022-162288

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C. V., Leventhal, J. R., Friedewald, J., Ho, B., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 6674–6675. https://doi.org/10.1182/blood-2022-164724

Mahadeo, K. M., Baiocchi, R. A., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Nikiforow, S., Reshef, R., Ye, W., & Prockop, S. (2022). New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 140(Supplement 1), 10374–10376. https://doi.org/10.1182/blood-2022-157766

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C., Leventhal, J. R., Ho, B., Friedewald, J., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD. Blood, 140(Supplement 1), 3833–3834. https://doi.org/10.1182/blood-2022-167812

Granat, L. M., Li, H., Anwer, F., Sheu, M., Faiman, B. M., Khouri, J., Mazzoni, S., Valent, J., Samaras, C. J., Chakraborty, R., Chaulagain, C. P., van Heeckeren, W. J., & Williams, L. S. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood, 140(Supplement 1), 4290–4291. https://doi.org/10.1182/blood-2022-168040

Wierda, W. G., Lewis, D. J., Ghia, P., Shah, N. N., Coombs, C. C., Cheah, C. Y., Lamanna, N., Rhodes, J. M., Hoffmann, M., Ma, S., Eyre, T. A., Munir, T., Patel, M. R., Alencar, A. J., Tam, C. S., Seymour, J. F., Jurczak, W., Lech-Marańda, E., Roeker, L. E., … Mato, A. R. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 846–849. https://doi.org/10.1182/blood-2022-157058

Zhou, P., Mansukhani, M. M., Toskic, D., Scalia, S., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM). Blood, 140(Supplement 1), 10048–10049. https://doi.org/10.1182/blood-2022-157790

Lewiecki, E. M., Bilezikian, J. P., Binkley, N., Bouxsein, M. L., Bukata, S. V., Dempster, D. W., Drake, M. T., McClung, M. R., Miller, P. D., Rosenthal, E., & Tosi, L. L. (2022). Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases. Journal of Clinical Densitometry, 25(4), 649–667. https://doi.org/10.1016/j.jocd.2022.10.002

Blachly, J. S., Stephens, D. M., Ye, J. C., Lamanna, N., Jain, N., Niesman, M., Zhang, K., & Woyach, J. A. (2022). Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL. Blood, 140(Supplement 1), 2324–2325. https://doi.org/10.1182/blood-2022-171203

Breyer, L. M., Wang, H., Gu, D., Johnstone, B. H., Ma, H., Woods, E. J., & Mapara, M. Y. (2022). Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice. Blood, 140(Supplement 1), 7347–7348. https://doi.org/10.1182/blood-2022-169787

Ford, M., Orlando, E., Jin, Z., Lipsky, A. H., Sawas, A., Pro, B., & Amengual, J. E. (2022). Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 3794–3795. https://doi.org/10.1182/blood-2022-163813

Akpoigbe, K., Culpepper-Morgan, J., Nwankwo, O., & Genao, A. (2022). Predicting Gastric Intestinal Metaplasia in a High-Risk Population. Cureus. https://doi.org/10.7759/cureus.31502

Tavakol, D. N., Fleischer, S., Falcucci, T., Graney, P. L., Halligan, S. P., Kaplan, D. L., & Vunjak-Novakovic, G. (2021). Emerging Trajectories for Next Generation Tissue Engineers. ACS Biomaterials Science & Engineering, 8(11), 4598–4604. https://doi.org/10.1021/acsbiomaterials.1c01428

Noguchi, M., Gkargkoulas, F., Matsumura, M., Kotinkaduwa, L. N., Hu, X., Usui, E., Fujimura, T., Seike, F., Salem, H., Jin, G., Li, C., Yamamoto, K., Sato, T., Redfors, B., Fall, K. N., Nazif, T. M., Ali, Z. A., Karmpaliotis, D., Parikh, S. A., … Maehara, A. (2022). Impact of Nonobstructive Left Main Coronary Artery Atherosclerosis on Long-Term Mortality. JACC: Cardiovascular Interventions, 15(21), 2206–2217. https://doi.org/10.1016/j.jcin.2022.08.024

Kondapalli, A. V., & Walker, M. D. (2022). Celiac disease and bone. Archives of Endocrinology and Metabolism, 66(5), 756–764. https://doi.org/10.20945/2359-3997000000561

Bandeira, F., Nóbrega, J. de M., Oliveira, L. B. de, & Bilezikian, J. (2022). Medical management of primary hyperparathyroidism. Archives of Endocrinology and Metabolism, 66(5), 689–693. https://doi.org/10.20945/2359-3997000000558

Hirsch, J. A., Michael, Y. L., Moore, K. A., Melly, S., Hughes, T. M., Hayden, K., Luchsinger, J. A., Jimenez, M. P., James, P., Besser, L. M., Sánchez, B., & Diez Roux, A. V. (2022). Longitudinal neighbourhood determinants with cognitive health and dementia disparities: protocol of the Multi-Ethnic Study of Atherosclerosis Neighborhoods and Aging prospective cohort study. BMJ Open, 12(11), e066971. https://doi.org/10.1136/bmjopen-2022-066971

Bandeira, L., Silva, B. C., & Bilezikian, J. P. (2022). Male osteoporosis. Archives of Endocrinology and Metabolism, 66(5), 739–747. https://doi.org/10.20945/2359-3997000000563

Hershman, D. L., Unger, J. M., Greenlee, H., Capodice, J., Lew, D. L., Darke, A., Minasian, L. M., Fisch, M. J., Henry, N. L., & Crew, K. D. (2022). Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain. JAMA Network Open, 5(11), e2241720. https://doi.org/10.1001/jamanetworkopen.2022.41720

Bandeira, F., Oliveira, L. B. de, & Bilezikian, J. P. (2022). Long-term consequences of osteoporosis therapy with denosumab. Archives of Endocrinology and Metabolism, 66(5), 717–723. https://doi.org/10.20945/2359-3997000000560

Horesh, D., Kohavi, S., Shilony-Nalaboff, L., Rudich, N., Greenman, D., Feuerstein, J. S., & Abbasi, M. R. (2022). Virtual Reality Combined with Artificial Intelligence (VR-AI) Reduces Hot Flashes and Improves Psychological Well-Being in Women with Breast and Ovarian Cancer: A Pilot Study. Healthcare, 10(11), 2261. https://doi.org/10.3390/healthcare10112261

Kim, W., Hecker, J., Barr, R. G., Boerwinkle, E., Cade, B., Correa, A., Dupuis, J., Gharib, S. A., Lange, L., London, S. J., Morrison, A. C., O’Connor, G. T., Oelsner, E. C., Psaty, B. M., Vasan, R. S., Redline, S., Rich, S. S., Rotter, J. I., … Yu, B. (2022). Assessing the contribution of rare genetic variants to phenotypes of chronic obstructive pulmonary disease using whole-genome sequence data. Human Molecular Genetics, 31(22), 3873–3885. https://doi.org/10.1093/hmg/ddac117

Benasi, G., Gostoli, S., Zhu, B., Offidani, E., Artin, M. G., Gagliardi, L., Rignanese, G., Sassi, G., Fava, G. A., & Rafanelli, C. (2022). Well-Being Therapy and Lifestyle Intervention in Type 2 Diabetes: A Pilot Randomized Controlled Trial. Psychosomatic Medicine, 84(9), 1041–1049. https://doi.org/10.1097/psy.0000000000001115

Wang, Q., Iketani, S., Li, Z., Guo, Y., Yeh, A. Y., Liu, M., Yu, J., Sheng, Z., Huang, Y., Liu, L., & Ho, D. D. (2022). Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host & Microbe, 30(11), 1512-1517.e4. https://doi.org/10.1016/j.chom.2022.09.002

Van Egeren, D., Kohli, K., Warner, J. L., Bedard, P. L., Riely, G., Lepisto, E., Schrag, D., LeNoue-Newton, M., Catalano, P., Kehl, K. L., Michor, F., Fiandalo, M., Foti, M., Khotskaya, Y., Lee, J., Peters, N., Sweeney, S., Abraham, J., … Walther, Z. (2022). Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-21448-1

Carey, R. M., Moran, A. E., & Whelton, P. K. (2022). Treatment of Hypertension. JAMA, 328(18), 1849. https://doi.org/10.1001/jama.2022.19590

Fernando, S. M., Scott, M., Talarico, R., Fan, E., McIsaac, D. I., Sood, M. M., Myran, D. T., Herridge, M. S., Needham, D. M., Hodgson, C. L., Rochwerg, B., Munshi, L., Wilcox, M. E., Bienvenu, O. J., MacLaren, G., Fowler, R. A., Scales, D. C., Ferguson, N. D., Combes, A., … Kyeremanteng, K. (2022). Association of Extracorporeal Membrane Oxygenation With New Mental Health Diagnoses in Adult Survivors of Critical Illness. JAMA, 328(18), 1827. https://doi.org/10.1001/jama.2022.17714

McAlpine, C. S., Kiss, M. G., Zuraikat, F. M., Cheek, D., Schiroli, G., Amatullah, H., Huynh, P., Bhatti, M. Z., Wong, L.-P., Yates, A. G., Poller, W. C., Mindur, J. E., Chan, C. T., Janssen, H., Downey, J., Singh, S., Sadreyev, R. I., Nahrendorf, M., Jeffrey, K. L., … Swirski, F. K. (2022). Sleep exerts lasting effects on hematopoietic stem cell function and diversity. Journal of Experimental Medicine, 219(11). https://doi.org/10.1084/jem.20220081

Benner, S. E., Eby, Y., Zhu, X., Fernandez, R. E., Patel, E. U., Ruff, J. E., Habtehyimer, F., Schmidt, H. A., Kirby, C. S., Hussain, S., Ostrander, D., Desai, N. M., Florman, S., Rana, M. M., Friedman-Moraco, R., Pereira, M. R., Mehta, S., Stock, P., Gilbert, A., … Tobian, A. A. R. (2022). The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir. JCI Insight, 7(21). https://doi.org/10.1172/jci.insight.162968

Sewanan, L. R., & Shimada, Y. J. (2022). Prospects for remodeling the hypertrophic heart with myosin modulators. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.1051564